Sana Therapeutics

GPTKB entity

Statements (52)
Predicate Object
gptkbp:instanceOf biotechnology company
gptkbp:businessModel research and development
biotech startup
partnerships with pharma
gptkbp:CEO Steve_Harr
gptkbp:clinicalTrials ongoing
Phase 1
data-driven decisions
rare diseases
Phase 2
Phase 3
innovative therapies
patient-centric approach
gptkbp:collaborations academic institutions
research organizations
biopharmaceutical companies
gptkbp:employees 50-100
gptkbp:focus gene therapy
gptkbp:founded 2018
gptkbp:founder Steve_Harr
gptkbp:funding gptkb:National_Institutes_of_Health
grants
venture capital
private investors
gptkbp:headquarters gptkb:San_Francisco,_California
https://www.w3.org/2000/01/rdf-schema#label Sana Therapeutics
gptkbp:investmentFocus $100 million
gptkbp:is_aimed_at neurological disorders
muscle disorders
gptkbp:leadership scientific advisory board
gptkbp:mission transform lives through gene therapy
gptkbp:partnerships gptkb:Duke_University
gptkb:University_of_California,_San_Francisco
gptkbp:products therapeutics for rare diseases
therapeutics for genetic disorders
therapeutics for inherited diseases
gptkbp:regulatoryCompliance FDA_approved
gptkbp:research therapeutic development
gptkbp:research_areas gptkb:Duchenne_muscular_dystrophy
amyotrophic lateral sclerosis
muscular dystrophy
cellular therapies
spinal muscular atrophy
genetic medicine
myotonic dystrophy
gptkbp:technology CRISPR technology
AAV gene delivery
gptkbp:tributaryOf multiple candidates
gptkbp:vision improving patient outcomes
leading gene therapy company
advancing genetic medicine
gptkbp:website www.sanatherapeutics.com